CYV Ceryvyn Therapeutics Limited
Healthcare · Biotechnology
· website
$0.01
52wk 0.01 – 0.60
Overall
—
Value
—
Growth
—
Health
—
Quality
—
Momentum
—
Dividend
—
Price
About Ceryvyn Therapeutics Limited
Ceryvyn Therapeutics Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company's pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME). It serves the biotechnology and healthcare industries. The company was formerly known as Opthea Limited and changed its name to Ceryvyn Therapeutics Limited in July 2026. Ceryvyn Therapeutics Limited was incorporated in 1984 and is headquartered in Melbourne, Australia.
Fundamental trends
Financial statements
Loading…
Key metrics
Market cap
$16.42M
P/E (trailing)
—
P/E (forward)
—
EPS (trailing)
-0.01
Dividend yield
—
Payout ratio
0.0%
Beta
1.50
EV / EBITDA
0.15
Price / Book
0.48
ROE
—
Operating margin
-706,200.0%
Net margin
0.0%
Total cash
$33.17M
Total debt
$0
Current ratio
19.52
Debt / Equity
—
Free cash flow
$-217.40M
Avg volume
28.38M
Latest annual results
(FY ending 30 Jun 2025)
- Revenue$25.00K
- Gross profit—
- Operating income-$152.31M
- Net income-$162.79M
- Diluted EPS-0.13
- Free cash flow-$158.66M
- Net debt-$48.44M